Key result
Aspirin use for primary prevention of cardiovascular and malignant diseases in healthy individuals is reviewed to assess whether it would be approved by regulatory authorities today.
Why the study?
Does aspirin prevent cardiovascular and malignant diseases in healthy individuals?
Does aspirin prevent cardiovascular and malignant diseases in healthy individuals?
This review evaluates the evidence for aspirin in the primary prevention of cardiovascular and malignant diseases and questions whether it would be approved for this indication today.
Answers are grounded in this paper and cite their sources.
Evidence questions aspirin's approvability for primary prevention today; leaves open refined risk-benefit trials in contemporary populations.
The role of aspirin for primary prevention in healthy individuals has been the subject of clinical trials for more than a quarter of a century. Because of this evidence, or sometimes despite it, many individuals self-administer aspirin to prevent cardiovascular events. This article reviews the published work for aspirin in primary prevention of cardiovascular and malignant diseases and considers whether aspirin would be approved by regulatory authorities for this use if it were to be marketed for this indication today.
No takes yet. Share an insight, caveat, or question.
Sepehr Shakib (2009) conducted a review in Primary prevention of cardiovascular and malignant diseases. Aspirin was evaluated. Aspirin use for primary prevention of cardiovascular and malignant diseases in healthy individuals is reviewed to assess whether it would be approved by regulatory authorities today.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: